Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) is now available.
Clarity Pharmaceuticals Ltd announced that the FDA has granted Fast Track Designation for its 64Cu-SAR-bisPSMA product, which aids in PET imaging of prostate cancer. Although the designation indicates FDA support, it doesn’t materially affect the company’s financial position but slightly increased the share price by 0.99%. The company emphasizes the importance of updating the market on such milestones, but notes that further clinical trials and regulatory approval are still required.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd operates in the biotechnology industry, focusing on the development of radiopharmaceuticals for cancer imaging and treatment. Its primary product is the 64Cu-SAR-bisPSMA, a compound used for PET imaging of prostate cancer.
YTD Price Performance: -20.86%
Average Trading Volume: 1,729,622
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$1.06B
See more insights into CU6 stock on TipRanks’ Stock Analysis page.
